OAM
XBIT icon

Oxford Asset Management’s XBiotech XBIT Stock Holding History

Oxford Asset Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-42,282
Closed -$452K – 904
2015
Q4 		$452K Buy
+42,282
New +$540K 0.01% 690

Other funds holding XBIT

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $67.5B AUM 28.09% 1-Year Est. Return
SF
Synovus Financial Columbus, Georgia $8.74B AUM 12.78% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Oxford Asset Management's XBIT Position: Q1 2016 in Review

Oxford Asset Management sold out of XBiotech (XBIT) in Q1 2016, closing a stake of 42,282 shares — an estimated $452K sold.

Oxford Asset Management first reported a position in XBIT in Q4 2015 and held it in 1 quarter. The position peaked at $452K in Q4 2015. 32 funds tracked by Wall St. Rank hold XBIT as of Q1 2016.

  • Oxford Asset Management reported no remaining XBiotech position as of Q1 2016 after selling out during the quarter.
  • Oxford Asset Management sold 42,282 XBiotech shares in Q1 2016, an estimated $452K.
  • Oxford Asset Management first reported a position in XBiotech in Q4 2015 and held it in 1 quarter.
  • Oxford Asset Management's XBiotech position peaked at $452K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held XBiotech as of Q1 2016.

Based on Oxford Asset Management's 13F filing for Q1 2016, filed 9 May 2016.